Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa

Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28.

Authors

Michael S Gelfand¹, Kerry O Cleveland¹

Affiliation

¹ Division of Infectious Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis.

PMID: 26021991
DOI: 10.1093/cid/civ411

No abstract available

Publication types

Letter

MeSH terms

Aged
Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Cephalosporins / administration & dosage
Cephalosporins / pharmacology
Cephalosporins / therapeutic use
Drug Resistance, Multiple, Bacterial
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Penicillanic Acid / administration & dosage
Penicillanic Acid / analogs & derivatives
Penicillanic Acid / pharmacology
Penicillanic Acid / therapeutic use
Pneumonia, Ventilator-Associated / drug therapy*
Pneumonia, Ventilator-Associated / microbiology
Pseudomonas Infections / drug therapy*
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects*
Tazobactam
Treatment Outcome

Substances

Anti-Bacterial Agents
Cephalosporins
ceftolozane, tazobactam drug combination
Penicillanic Acid
Tazobactam